Publications by authors named "Y Hyodo"
Background: This study aimed to investigate the association between the Fc-gamma receptor IIIA (FCGR3A) 158 polymorphism and clinical outcomes in kidney transplantation (KTx) patients. Specifically, we focused on late-onset neutropenia (LON) in ABO-incompatible (ABOi) or HLA-incompatible (HLAi) KTx recipients who underwent rituximab (RTx) desensitization therapy.
Methods: FCGR3A 158F/V polymorphisms were identified in 85 ABOi or HLAi KTx recipients who underwent RTx desensitization at our institution between April 2008 and October 2021.
Background: Surgery for inferior vena cava tumor thrombus (IVC-TT) in patients with renal cell carcinoma (RCC) is highly invasive and is associated with perioperative mortality. This study aimed to assess the efficacy of presurgical systemic therapy (PT) on perioperative outcomes in RCC patients with IVC-TT.
Methods: A total of 68 patients with right-sided RCC and level ≥ II IVC-TT were included in this study.
Background: A survival advantage with apalutamide (APA) combined with androgen deprivation therapy for metastatic castration-sensitive prostate cancer (mCSPC) has been demonstrated in the clinical trial, irrespective of race. However, the incidence of APA-induced skin rash in the Japanese subpopulation is higher than that in the global population. In the present study, we investigated the predictive value of APA dose per body weight for the incidence of skin rash.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the effectiveness of neoadjuvant therapy in improving outcomes for patients with non-metastatic renal cell carcinoma (RCC) accompanied by inferior vena cava (IVC) thrombus prior to surgical resection.
- Data from 2006 to 2024 showed that patients receiving neoadjuvant therapy had smaller tumor sizes and better survival rates compared to those who did not receive this treatment.
- Findings indicate that neoadjuvant therapy can lead to significantly improved disease-free survival (DFS) and overall survival (OS) for these patients, highlighting its potential as a beneficial preoperative treatment option.
Article Synopsis
- The study aimed to explore how tumor size affects the prognosis of patients with metastatic renal cell carcinoma (mRCC) receiving two different treatment approaches: dual immune checkpoint inhibitors (IOIO) and a combination of immune checkpoint inhibitors with tyrosine kinase inhibitors (IOTKI).
- Researchers analyzed data from 180 mRCC patients to evaluate the impact of tumor size on progression-free survival (PFS) and overall survival (OS), finding that it was a significant predictor especially in the IOIO group.
- The results suggest that tumor size should be prioritized in treatment decisions for renal cancer, particularly for patients undergoing IOIO therapy, as it offered better prognostic insights than other factors like nephrectomy status and IMDC risk classification